Key facts
- Vestal Point Capital, LP filed SCHEDULE 13G/A for Lexeo Therapeutics, Inc. Common Stock, par value $0.0001 per share (LXEO).
- Disclosed ownership: 7.5%.
- Date of event: 30 Sep 2025.
Vestal Point Capital, LP - 30 Sep 2025 SCHEDULE 13G/A Report for Lexeo Therapeutics, Inc. Common Stock, par value $0.0001 per share (LXEO)
- Filing manager
- Vestal Point Capital, LP
- Reporting owner
- Vestal Point Capital, LP
- Symbol
- LXEO
- Shares outstanding
- 54,897,360 shares
- Disclosed shares
- 4,117,302 shares
- Ownership percentage
- 7.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 16:00:23 UTC
- Event date
- 30 Sep 2025
- Previous filing
- 14 Aug 2025
- SEC filing
- View on sec.gov
Reporting parties
Subject security
Ownership signal
SEC evidence
Key filing fact
Vestal Point Capital, LP disclosed 7.5% ownership in Lexeo Therapeutics, Inc. Common Stock, par value $0.0001 per share (LXEO) on 30 Sep 2025.
Change
- Previous schedule filing date: 14 Aug 2025.
- Current filing was accepted on 14 Nov 2025, 16:00.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vestal Point Capital, LP | 7.5% | 4,117,302 | 0 | 4,117,302 | /s/ Ryan Wilder | By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner | |
| Ryan Wilder | 7.5% | 4,117,302 | 0 | 4,117,302 | /s/ Ryan Wilder | Ryan Wilder, Individually |
CIK / CUSIP context first